Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Severe tremor after cotrimoxazole-induced elevation of venlafaxine serum concentrations in a patient with major depressive disorder.

Geber C, Ostad Haji E, Schlicht K, Hiemke C, Tadić A.

Ther Drug Monit. 2013 Jun;35(3):279-82. doi: 10.1097/FTD.0b013e31828816e0.

PMID:
23666577
2.

Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine.

McAlpine DE, Biernacka JM, Mrazek DA, O'Kane DJ, Stevens SR, Langman LJ, Courson VL, Bhagia J, Moyer TP.

Ther Drug Monit. 2011 Feb;33(1):14-20. doi: 10.1097/FTD.0b013e3181fcf94d.

PMID:
21099743
3.

PharmGKB summary: venlafaxine pathway.

Sangkuhl K, Stingl JC, Turpeinen M, Altman RB, Klein TE.

Pharmacogenet Genomics. 2014 Jan;24(1):62-72. doi: 10.1097/FPC.0000000000000003. Review. No abstract available.

4.

Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine.

Grözinger M, Dragicevic A, Hiemke C, Shams M, Müller MJ, Härtter S.

Pharmacopsychiatry. 2003 Jan;36(1):3-6.

PMID:
12649767
5.

Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups.

Waade RB, Hermann M, Moe HL, Molden E.

Eur J Clin Pharmacol. 2014 Aug;70(8):933-40. doi: 10.1007/s00228-014-1696-8. Epub 2014 May 27.

PMID:
24858822
6.

Severe acute cardiomyopathy associated with venlafaxine overdose and possible role of CYP2D6 and CYP2C19 polymorphisms.

Vinetti M, Haufroid V, Capron A, Classen JF, Marchandise S, Hantson P.

Clin Toxicol (Phila). 2011 Nov;49(9):865-9. doi: 10.3109/15563650.2011.626421.

PMID:
22077251
8.

The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population.

Fukuda T, Nishida Y, Zhou Q, Yamamoto I, Kondo S, Azuma J.

Eur J Clin Pharmacol. 2000 May;56(2):175-80.

PMID:
10877013
9.

A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine.

Jornil J, Nielsen TS, Rosendal I, Ahlner J, Zackrisson AL, Boel LW, Brock B.

Forensic Sci Int. 2013 Mar 10;226(1-3):e26-31. doi: 10.1016/j.forsciint.2012.12.020. Epub 2013 Jan 17.

PMID:
23332809
10.

Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder.

Lobello KW, Preskorn SH, Guico-Pabia CJ, Jiang Q, Paul J, Nichols AI, Patroneva A, Ninan PT.

J Clin Psychiatry. 2010 Nov;71(11):1482-7. doi: 10.4088/JCP.08m04773blu. Epub 2010 Apr 6.

PMID:
20441720
11.

Serotonin toxicity in a CYP2D6 poor metabolizer, initially diagnosed as a drug-resistant major depression.

Gressier F, Ellul P, Dutech C, Ait Tayeb Ael K, Monfort J, Corruble E, Becquemont L, Hardy P, Verstuyft C.

Am J Psychiatry. 2014 Aug;171(8):890. doi: 10.1176/appi.ajp.2014.13101377. No abstract available.

PMID:
25082493
12.

Drug interactions and pharmacogenomics in the treatment of breast cancer and depression.

Henry NL, Stearns V, Flockhart DA, Hayes DF, Riba M.

Am J Psychiatry. 2008 Oct;165(10):1251-5. doi: 10.1176/appi.ajp.2008.08040482. Review. No abstract available.

13.

Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans.

Lessard E, Yessine MA, Hamelin BA, O'Hara G, LeBlanc J, Turgeon J.

Pharmacogenetics. 1999 Aug;9(4):435-43.

PMID:
10780263
14.

CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP.

Huezo-Diaz P, Perroud N, Spencer EP, Smith R, Sim S, Virding S, Uher R, Gunasinghe C, Gray J, Campbell D, Hauser J, Maier W, Marusic A, Rietschel M, Perez J, Giovannini C, Mors O, Mendlewicz J, McGuffin P, Farmer AE, Ingelman-Sundberg M, Craig IW, Aitchison KJ.

J Psychopharmacol. 2012 Mar;26(3):398-407. doi: 10.1177/0269881111414451. Epub 2011 Sep 17.

PMID:
21926427
15.

Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype.

van der Weide J, van Baalen-Benedek EH, Kootstra-Ros JE.

Ther Drug Monit. 2005 Aug;27(4):478-83.

PMID:
16044105
16.
17.

Novel CYP2D6 and CYP2C19 variants identified in a patient with adverse reactions towards venlafaxine monotherapy and dual therapy with nortriptyline and fluoxetine.

Chua EW, Foulds J, Miller AL, Kennedy MA.

Pharmacogenet Genomics. 2013 Sep;23(9):494-7. doi: 10.1097/FPC.0b013e328363688d.

PMID:
23799451
18.

CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.

Shams ME, Arneth B, Hiemke C, Dragicevic A, Müller MJ, Kaiser R, Lackner K, Härtter S.

J Clin Pharm Ther. 2006 Oct;31(5):493-502.

PMID:
16958828
19.

Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.

Preskorn SH, Kane CP, Lobello K, Nichols AI, Fayyad R, Buckley G, Focht K, Guico-Pabia CJ.

J Clin Psychiatry. 2013 Jun;74(6):614-21. doi: 10.4088/JCP.12m07807. Epub 2013 Mar 13.

PMID:
23541126
20.

Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression.

Ng C, Sarris J, Singh A, Bousman C, Byron K, Peh LH, Smith DJ, Tan CH, Schweitzer I.

Hum Psychopharmacol. 2013 Sep;28(5):516-22. doi: 10.1002/hup.2340.

PMID:
24014145

Supplemental Content

Support Center